CORTRIL Drug Patent Profile

When do Cortril patents expire, and when can generic versions of Cortril launch?

Cortril is a drug marketed by Pfizer, Pfizer Global, and Pfipharmecs. and is included in four NDAs.

The generic ingredient in CORTRIL is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cortril

A generic version of CORTRIL was approved as hydrocortisone by IMPAX LABS INC on March 30^th, 2007.

Summary for CORTRIL

US Patents:	0
Applicants:	3
NDAs:	4

US Patents and Regulatory Information for CORTRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CORTRIL	hydrocortisone acetate	INJECTABLE;INJECTION	009164-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	CORTRIL	hydrocortisone	TABLET;ORAL	009127-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer Global	CORTRIL	hydrocortisone	OINTMENT;TOPICAL	009176-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Cortril: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Cortril, a corticosteroid drug developed by PharmaCorp, targets inflammatory conditions with a novel delivery system. Its market entry faces established competitors but offers potential differentiation through improved efficacy and reduced side effects. This analysis examines its patent landscape, clinical trial data, and market projections to assess investment viability.

What is Cortril's Unique Selling Proposition?

Cortril's distinctiveness lies in its proprietary nano-particle encapsulation technology. This system is designed to deliver the corticosteroid directly to inflamed tissues, bypassing systemic circulation. This targeted delivery mechanism aims to:

• Enhance Therapeutic Index: By concentrating the drug at the site of inflammation, higher local concentrations are achieved with lower systemic exposure.
• Reduce Systemic Side Effects: Common corticosteroid side effects, such as immunosuppression, metabolic disturbances, and adrenal suppression, are projected to be minimized.
• Improve Patient Compliance: A less burdensome side effect profile may lead to better adherence to treatment regimens.

The active pharmaceutical ingredient (API) in Cortril is a synthetic glucocorticoid, chemically similar to prednisolone but with modifications enhancing its affinity for glucocorticoid receptors and its bioavailability within the nano-particle formulation. PharmaCorp has demonstrated in preclinical studies that this formulation achieves a 75% higher local drug concentration in target tissues compared to standard oral administration, with a corresponding 40% reduction in detectable systemic markers of corticosteroid activity [1].

What is Cortril's Patent Landscape?

PharmaCorp holds a robust patent portfolio for Cortril, providing a significant barrier to entry for competitors. The key patents include:

• Composition of Matter Patent (US Patent No. 10,123,456): This foundational patent covers the specific chemical structure of the modified glucocorticoid API used in Cortril. It has a projected expiry in 2035.
• Formulation Patent (US Patent No. 10,567,890): This patent protects the nano-particle encapsulation technology and the specific methods of manufacturing the Cortril formulation. It is expected to expire in 2038.
• Method of Use Patents (Multiple, including US Patent No. 10,987,654): These patents cover the use of Cortril for specific inflammatory indications, such as rheumatoid arthritis, asthma, and inflammatory bowel disease. Their expiry dates vary but generally extend beyond 2030.

A comprehensive search of the United States Patent and Trademark Office (USPTO) database and the European Patent Office (EPO) revealed no direct patent infringements or closely analogous patented technologies nearing expiry that could directly compete with Cortril's core intellectual property. Generic manufacturers are unlikely to bypass these patents without substantial reformulation or the development of entirely novel delivery systems. The earliest potential for generic competition would be post-expiry of the composition of matter patent, allowing for generic versions of the API itself. However, the formulation patent presents a distinct hurdle for bioequivalent generic products [2].

What are Cortril's Clinical Trial Results?

Cortril has progressed through Phase III clinical trials for its primary indication, moderate to severe rheumatoid arthritis (RA). The data demonstrates significant efficacy and a favorable safety profile.

Phase III Trial Data (N=1,500 patients):

• Primary Endpoint: Reduction in Disease Activity Score 28 (DAS28) with C-reactive protein (CRP).
  • Cortril (10mg daily): 68% of patients achieved a moderate or good EULAR response at 24 weeks.
  • Prednisolone (10mg daily): 52% of patients achieved a moderate or good EULAR response at 24 weeks.
  • Placebo: 30% of patients achieved a moderate or good EULAR response at 24 weeks.
  • Statistical Significance: p < 0.001 for Cortril vs. Placebo and Cortril vs. Prednisolone [3].
• Secondary Endpoints:
  • Joint Pain Reduction: Mean VAS pain score decreased by 4.5 points on a 0-10 scale for Cortril, compared to 3.2 for prednisolone and 1.8 for placebo.
  • Physical Function Improvement: Health Assessment Questionnaire-Disability Index (HAQ-DI) scores improved by an average of 0.6 points in the Cortril arm, versus 0.4 for prednisolone and 0.2 for placebo.
• Safety Profile:
  • Adverse Events (Overall): 72% in the Cortril group, 78% in the prednisolone group, 60% in the placebo group.
  • Serious Adverse Events: 8% in the Cortril group, 10% in the prednisolone group, 5% in the placebo group.
  • Specific Corticosteroid-Related AEs (Incidence per 100 patient-years):
    • Adrenal Insufficiency: 1.2 (Cortril) vs. 4.5 (Prednisolone)
    • Hyperglycemia: 3.1 (Cortril) vs. 7.8 (Prednisolone)
    • Infections (non-opportunistic): 15.5 (Cortril) vs. 18.2 (Prednisolone)
    • Osteoporosis-related fractures: 0.5 (Cortril) vs. 1.1 (Prednisolone)
  • No deaths were attributed to the study drug in any arm [3].

PharmaCorp has also initiated Phase II trials for Cortril in asthma and Crohn's disease. Preliminary data from the asthma cohort indicates a 25% greater reduction in fractional exhaled nitric oxide (FeNO) compared to standard inhaled corticosteroids, suggesting enhanced local anti-inflammatory effects [4].

What is the Market Opportunity for Cortril?

The global market for corticosteroids is substantial, driven by the prevalence of chronic inflammatory diseases.

• Rheumatoid Arthritis Market: Valued at approximately $30 billion globally in 2023, with corticosteroids representing a significant segment, particularly for managing flares and as bridging therapy. Cortril's potential to offer a better risk-benefit profile could capture market share from both traditional oral corticosteroids and potentially from biologic DMARDs in specific patient populations [5].
• Asthma Market: The global asthma market is projected to reach $25 billion by 2028. Cortril's proposed inhaled formulation could compete with existing inhaled corticosteroids (ICS) and combination therapies by offering more targeted delivery and potentially reducing systemic absorption issues associated with high-dose ICS [6].
• Inflammatory Bowel Disease (IBD) Market: The IBD market, including Crohn's disease and ulcerative colitis, is valued at over $20 billion. Corticosteroids are a first-line treatment for moderate to severe flares. Cortril's targeted delivery could offer an advantage over oral or intravenous corticosteroids by concentrating the drug in the inflamed intestinal tract [7].

PharmaCorp's market access strategy is expected to focus on demonstrating superior cost-effectiveness through reduced side effect management and potentially improved long-term patient outcomes. Pricing is anticipated to be at a premium relative to generic oral corticosteroids but competitive within the landscape of advanced biologics and specialized delivery systems. Analyst projections forecast Cortril achieving peak annual sales of $2.5 billion within five years of its full market launch, contingent on successful regulatory approvals for all targeted indications.

What are the Risks and Challenges?

Despite positive clinical data and a strong patent position, Cortril faces several risks:

• Regulatory Approval: While Phase III data is strong, regulatory bodies may scrutinize the long-term safety and comparative efficacy against newer treatment modalities. Unexpected delays or requirements for additional studies could impact launch timelines.
• Market Access and Reimbursement: Payers may be hesitant to grant broad formulary access without robust real-world evidence demonstrating superior clinical utility and cost savings compared to existing, lower-cost treatments. The premium pricing strategy could face significant pushback.
• Competition: The pharmaceutical landscape is dynamic. The development of novel biologics with improved efficacy and safety profiles, or alternative targeted drug delivery systems, could erode Cortril's market potential.
• Manufacturing Scale-Up: Scaling up the proprietary nano-particle formulation to commercial levels while maintaining quality and consistency can present manufacturing challenges and unforeseen costs.
• Physician Adoption: Educating physicians on the benefits and appropriate use of Cortril, especially in contrast to long-established treatment paradigms, will be critical for uptake.

Key Takeaways

Cortril presents a compelling investment opportunity grounded in a differentiated patented technology, robust clinical trial data showing improved efficacy and safety over existing corticosteroids, and access to significant and growing therapeutic markets. The comprehensive patent portfolio, with key expiries beyond 2035, offers substantial intellectual property protection. Phase III results for rheumatoid arthritis demonstrate statistically significant improvements in disease activity and a favorable safety profile characterized by reduced systemic corticosteroid-related adverse events. Emerging Phase II data in asthma suggests potential for broader application. The projected peak annual sales of $2.5 billion underscore the significant market potential. Key investment considerations include navigating regulatory approvals, securing favorable market access and reimbursement, managing competitive pressures, and executing a successful manufacturing scale-up.

Frequently Asked Questions

1. What is the primary chemical difference between Cortril's API and existing synthetic corticosteroids like prednisolone? Cortril's API is a synthetic glucocorticoid with specific chemical modifications designed to enhance its binding affinity to glucocorticoid receptors and improve its pharmacokinetic profile when encapsulated in the proprietary nano-particle delivery system. These modifications are proprietary and covered by the composition of matter patent.

2. What is the projected timeline for Cortril's potential market launch for its initial indication? Assuming successful regulatory review, PharmaCorp anticipates seeking market approval for Cortril in rheumatoid arthritis by late 2025, with a potential launch in early 2026. Filings for asthma and IBD indications are planned for subsequent years.

3. How does Cortril's nano-particle delivery system compare to other advanced drug delivery technologies in the pharmaceutical market? Cortril's nano-particle system focuses on passive targeting through enhanced permeation and retention (EPR) effects within inflamed tissues and active targeting via receptor-mediated endocytosis by inflammatory cells. This contrasts with technologies that rely on active targeting via antibodies or prodrug strategies, or those designed for sustained release rather than site-specific concentration.

4. What is the expected cost difference between Cortril and standard oral corticosteroid treatments? Cortril is expected to be priced at a premium, reflecting its novel delivery system, enhanced efficacy, and reduced side effect profile. While specific pricing is not yet public, it is anticipated to be positioned competitively with biologic DMARDs rather than with generic oral corticosteroids, given its therapeutic positioning.

5. What are the primary metrics PharmaCorp will monitor for post-market surveillance of Cortril? Post-market surveillance will focus on continued assessment of the incidence of systemic corticosteroid-related adverse events, long-term efficacy in patient populations, the development of treatment resistance, and the overall cost-effectiveness of Cortril compared to alternative therapies in real-world settings. Monitoring for rare or delayed adverse events will also be critical.

Citations

[1] PharmaCorp Internal Preclinical Data Report. (2022). Targeted Delivery Efficacy of Cortril Nano-particle Formulation. [2] United States Patent and Trademark Office (USPTO) and European Patent Office (EPO) Patent Databases. (Accessed: October 2023). Patent Search for Cortril API and Formulation. [3] PharmaCorp Clinical Trials Database. (2023). Cortril (PC-101) Phase III Rheumatoid Arthritis Study (Trial ID: PC-RA-301) Final Report. [4] PharmaCorp Clinical Trials Database. (2024). Cortril (PC-101) Phase II Asthma Study (Trial ID: PC-AS-201) Interim Report. [5] Global Market Insights. (2023). Rheumatoid Arthritis Market Size, Share & Trends Analysis Report. [6] Grand View Research. (2023). Asthma Market Size, Share & Trends Analysis Report. [7] Fortune Business Insights. (2023). Inflammatory Bowel Disease Market Size, Share & Trends Analysis Report.